MARKET

XGN

XGN

Exagen Inc.
NASDAQ
3.500
+0.130
+3.86%
After Hours: 3.470 -0.03 -0.86% 19:17 02/10 EST
OPEN
3.390
PREV CLOSE
3.370
HIGH
3.690
LOW
3.365
VOLUME
404.83K
TURNOVER
--
52 WEEK HIGH
12.23
52 WEEK LOW
2.670
MARKET CAP
79.32M
P/E (TTM)
-3.7809
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XGN last week (0202-0206)?
Weekly Report · 1d ago
Weekly Report: what happened at XGN last week (0126-0130)?
Weekly Report · 02/02 09:15
Exagen Price Target Cut to $8.00/Share From $18.00 by B. Riley Securities
Dow Jones · 01/30 14:01
B. Riley Securities Reiterates Buy on Exagen, Lowers Price Target to $8
Benzinga · 01/30 13:52
Exagen price target lowered to $8 from $18 at B. Riley
TipRanks · 01/30 13:37
EXAGEN INC <XGN.O>: B. RILEY CUTS TARGET PRICE TO $8 FROM $18
Reuters · 01/30 13:18
3 Best Stocks to Buy Today, 1/26/2026, According to Top Analysts
TipRanks · 01/26 13:39
Exagen: Temporary Headwinds, Strong AVISE Volume, and Undervalued Long‑Term Upside Support Buy Rating and $15 Target
TipRanks · 01/26 12:06
More
About XGN
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

Webull offers Exagen Inc stock information, including NASDAQ: XGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XGN stock methods without spending real money on the virtual paper trading platform.